Is PODD a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Installed base compounding through pods, with revenue (ttm) at ~$3.05B. The bear case rests on type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes. Analysts covering it are spread from $172.00 to $360.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $172.00, +29.1% from the $133.26 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Installed base compounding through pods. Every new Omnipod user becomes a recurring consumable customer who buys pods indefinitely, so revenue is far less dependent on new-unit sales than a durable device business. The most optimistic analyst target on PODD is $360.00, +170.1% from the $133.26 price. That figure is only reachable if this thesis works close to its best case.

Type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes. Concentration is structural, since one product family is effectively the entire company and any manufacturing, supply or reimbursement disruption hits all of revenue at once. Competition is intensifying from Tandem's Mobi, Medtronic's MiniMed 780G, Beta Bionics and Sequel, and CGM partners Dexcom and Abbott are both suppliers and potential rivals as the category converges. GLP-1 adoption is an unquantified swing factor for the insulin-intensive type 2 population that Insulet is counting on. Finally, the stock carries growth-stock beta: it lost more than half its value from the 52-week high on a guidance cut that was small in dollar terms, which is how the market prices a business valued on its growth rate. The most pessimistic published target is $172.00, +29.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Insulet makes the Omnipod, a tubeless wearable insulin pump, and earns most of its revenue from the recurring disposable pods rather than the hardware.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Installed base compounding through pods) stalling in the reported numbers rather than in the narrative, the risk above (type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Insulet sells the Omnipod, a tubeless insulin pump worn as a small adhesive pod on the body. The pod holds insulin and is discarded and replaced roughly every three days, so users buy a continuous supply. The current Omnipod 5 system pairs with a Dexcom or Abbott continuous glucose monitor and adjusts basal insulin automatically. Pods are the overwhelming majority of revenue; a small drug delivery segment is under 2% and shrinking.

Insulet beat second-quarter estimates with ~$802 million of revenue and ~$1.66 adjusted EPS, then cut full-year US Omnipod growth guidance to ~17-19%. The reason mattered more than the number: type 2 diabetes customers are leaving at meaningfully higher rates than type 1 customers, mostly within the first 90 days. Shares fell about 20% because type 2 adoption was the core long-term growth argument, and the preliminary 2027 view of mid-teens growth compounded the disappointment.

The Omnipod is a razor-and-blade business. There is no expensive durable pump to finance; the recurring revenue comes from disposable pods replaced every three days for as long as the person stays on therapy. That means lifetime value is almost entirely a function of retention, and it explains why a retention problem in a specific patient cohort translates directly into a revenue guidance cut rather than a one-quarter miss.